<DOC>
	<DOCNO>NCT01655992</DOCNO>
	<brief_summary>Comparing S1 generic With Capecitabine Patients With Metastatic Breast Cancer .</brief_summary>
	<brief_title>A Trial Comparing S1 Generic With Capecitabine Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description>Comparing S1 generic ( Tegafur，Gimeracil Oteracil Potassium Capsules ) With Capecitabine Patients With Metastatic Breast Cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Histologically confirm breast cancer Pretreated metastatic breast cancer 2 line chemotherapy Have previously treat capecitabine , oral fluracil ECOG performance status ≤ 1 Be female ≥ 18 ≤ 75 year age Have least one target lesion accord RECIST criterion 1.1 Pregnant lactate woman ECOG ≥ 2 Have treat capecitabine Evidence CNS metastasis History another malignancy within last five year except cure basal cell carcinoma skin carcinoma insitu uterine cervix contralateral breast cancer Abnormal laboratory value : hemoglobin &lt; 10.0 g/dl , absolute neutrophil count &lt; 1.5×10^9/L , platelet count &lt; 100×10^9/L , serum creatinine &gt; upper limit normal ( ULN ) , serum bilirubin &gt; ULN , ALT AST &gt; 5×ULN , AKP &gt; 5×ULN Serious uncontrolled intercurrent infection Life expectancy le 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>Tegafur，Gimeracil Oteracil Potassium Capsules</keyword>
</DOC>